Your data pipeline isn't just a back-end function. It's the intelligence layer that decides whether your business acts before competitors do or catches up after the fact. Finding a trusted full ...

As the Premier League season nears its conclusion, who are favourites to secure a place in Europe next season, and how many ...

Trials of the British Army’s Ajax armoured vehicles are set to resume, despite major delays amid concern for soldiers’ safety. Minister for Defence Readiness and Industry Luke Pollard announced in ...

Trials of the British Army's Ajax armoured vehicle will be "proceeding cautiously" after they were halted last year, a defence minister has said. A decision was made to stop using the Ajax after ...

Add Yahoo as a preferred source to see more of our stories on Google. Colonel Hamish de Bretton Gordon, late of the Royal Tank Regiment, prepares to test drive the Ajax for the Telegraph The most ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Eli Lilly said on Monday it would buy privately held blood cancer treatment developer ‌Ajax Therapeutics ⁠for up ⁠to $2.3 billion in cash. Ajax's lead asset, AJ1-11095, is an experimental once-daily ...

Eli Lilly LLY-0.00%increase; green up pointing triangle continued its recent buying spree, agreeing to pay up to $2.3 billion for Ajax Therapeutics in a deal that bolsters the drugmaker’s blood-cancer ...

Eli Lilly (LLY) has agreed to acquire biopharmaceutical company Ajax Therapeutics for up to $2.3B in cash, inclusive of an upfront payment and subsequent payments upon the achievement of certain ...

Eli Lilly said on Monday it would buy privately held cancer drug developer Ajax Therapeutics for up to $2.3 billion in cash, as the U.S. drugmaker looks to expand its oncology pipeline. Lilly has been ...

April 27 (Reuters) - Eli Lilly (LLY.N), opens new tab said on Monday it would buy privately held cancer drug developer Ajax Therapeutics for up ‌to $2.3 billion in cash, as the U.S. drugmaker looks to ...

Eli Lilly & Co. agreed to buy closely held Ajax Therapeutics Inc. for as much as $2.3 billion in cash, part of its effort to build out a portfolio of breakthrough cancer therapies. Ajax’s lead ...